AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “hold” rating reissued by investment analysts at B. Riley in a research report issued to clients and investors on Tuesday. They currently have a $16.00 target price on the specialty pharmaceutical company’s stock. B. Riley’s price target would suggest a potential upside of 9.78% from the stock’s previous close.

A number of other equities analysts have also weighed in on AMAG. Cantor Fitzgerald restated a “hold” rating and set a $21.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Morgan Stanley lowered their price target on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, November 3rd. Finally, Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Wednesday, October 4th. Twelve analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $21.27.

AMAG Pharmaceuticals (NASDAQ:AMAG) traded up $0.17 during mid-day trading on Tuesday, hitting $14.58. 175,279 shares of the stock were exchanged, compared to its average volume of 833,256. The stock has a market capitalization of $509.39, a PE ratio of -2.40 and a beta of 0.79. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94. AMAG Pharmaceuticals has a twelve month low of $11.93 and a twelve month high of $25.20.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. equities research analysts expect that AMAG Pharmaceuticals will post -4.17 earnings per share for the current year.

A number of large investors have recently bought and sold shares of AMAG. State Street Corp boosted its holdings in AMAG Pharmaceuticals by 10.6% in the 2nd quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock valued at $51,336,000 after purchasing an additional 267,873 shares during the last quarter. Tocqueville Asset Management L.P. acquired a new position in AMAG Pharmaceuticals in the 3rd quarter valued at about $3,958,000. Prudential Financial Inc. boosted its holdings in AMAG Pharmaceuticals by 35.7% in the 3rd quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock valued at $13,382,000 after purchasing an additional 190,660 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in AMAG Pharmaceuticals by 18.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock valued at $22,361,000 after purchasing an additional 189,576 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in AMAG Pharmaceuticals by 46.1% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 424,875 shares of the specialty pharmaceutical company’s stock valued at $7,839,000 after purchasing an additional 134,080 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “AMAG Pharmaceuticals (AMAG) Given “Hold” Rating at B. Riley” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/amag-pharmaceuticals-amag-given-hold-rating-at-b-riley/1809320.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.